Menu

A T-Cell Tweak Combats Advanced Breast Cancer

The immunotherapy eliminated a woman’s metastatic lesions and kept her disease-free for two years.

Jun 5, 2018
Ashley Yeager

ISTOCK, MELETIOS VERRASReactivating T cells in a woman with metastatic breast cancer eliminated her tumors, researchers report today (June 4) in Nature Medicine. It is the first time late-stage breast cancer has been successfully treated with T-cell immunotherapy.

“We’re looking for a treatment—an immunotherapy—that can be broadly used in patients with common cancers,” study coauthor Steven Rosenberg, an oncologist and immunologist at the National Cancer Institute (NCI), tells NPR. The result suggests this type of treatment might be possible for other types of solid tumors, including in the colon, rectum, and pancreas.

To develop the treatment, Rosenberg and his colleagues used whole-exome and RNA sequencing to identify point mutations within the genome of a patient’s breast tumor and then isolated tumor-infiltrating lymphocytes from the mass and identified which ones were reactive against mutations in the genes SLC3A2, ECPAS, CADPS2, and CTSB, which were present in her tumor. The researchers then infused into the patient roughly 90 billion tumor-infiltrating lymphocytes that targeted the four mutant genes. In addition, she received treatment with an anti–programmed cell death protein 1 antibody two days before the T-cell transfer, along with antibody infusions three, six, and nine weeks after it. Her tumors disappeared.

Such a result is “an unprecedented response in such advanced breast cancer,” writes Laszlo Radvanyi of the Ontario Institute for Cancer Research in Toronto in an accompanying Nature Medicine News & Views article.

Still, Rosenberg notes to NPR, the treatment won’t work for everyone. Two other patients with breast cancer failed to respond to the therapy. But the approach has helped seven patients, including individuals with colon, liver, or cervical cancer. “Is it ready for prime time today? No,” Rosenberg says. “Can we do it in most patients today? No.” But, “I think it’s the most promising treatment now being explored for solving the problem of the treatment of metastatic, common cancers,” he says.

“This is an illustrative case report that highlights, once again, the power of immunotherapy,” Tom Misteli, director of the Center for Cancer Research at NCI who was not involved in the study, tells Forbes. “If confirmed in a larger study, it promises to further extend the reach of this T-cell therapy to a broader spectrum of cancers.”

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.
Corning Introduces New 1536-well Spheroid Microplate
Corning Introduces New 1536-well Spheroid Microplate
High-throughput spheroid microplate benefits cancer research, drug screening